HCW Biologics Inc. reports material agreement in SEC 8-K

HCW Biologics Inc. filed an 8-K covering a material definitive agreement, an unregistered sale of equity securities, a Regulation FD disclosure, and other material corporate events. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.